Scholarlink

<p>Depending on the risk status, the treatment options for non-muscle-invasive bladder cancer (NMIBC) can include a&#xa0;bladder-preserving strategy with intravesical instillation treatment or early radical cystectomy. Established intravesical treatment options such as mitomycin&#xa0;C (MMC) or Bacillus Calmette-Guérin (BCG) are available to reduce the probability of progression and recurrence. This article classifies the intravesical treatment options in the therapeutic landscape of NMIBC and provides an overview of the indications and application regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intravesikale Therapie des nicht muskelinvasiven Urothelkarzinoms der Harnblase

  • 期刊论文

  • 发表日期：

    2025年2月27日

查看全文
  • Henning Bahlburg,
  • Joachim Noldus,
  • Florian Roghmann

摘要

Depending on the risk status, the treatment options for non-muscle-invasive bladder cancer (NMIBC) can include a bladder-preserving strategy with intravesical instillation treatment or early radical cystectomy. Established intravesical treatment options such as mitomycin C (MMC) or Bacillus Calmette-Guérin (BCG) are available to reduce the probability of progression and recurrence. This article classifies the intravesical treatment options in the therapeutic landscape of NMIBC and provides an overview of the indications and application regimens.